Pharmaceuticals, Biotechnology and Life Sciences
ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies…
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate…
FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical…
Increased Product Sales to $133 Million in 2024Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million,…
– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating…
– Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study;…
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3…
IRVINE, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Nymox announces that it dismissed the Delaware matter pending against Ascella on…
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster…
TUSCALOOSA, Ala., March 10, 2025 (GLOBE NEWSWIRE) — Druid City Vital Care (“Druid City”) was recently recognized at the Vital…